Panbela initiates a randomized, double-blind, placebo-controlled study (aspire) of nab-paclitaxel and gemcitabine with or without sbp-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma

Minneapolis, jan. 26, 2022 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the initiation of the company's global phase 2 clinical trial of sbp-101 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, which is referred to as the aspire trial.
PBLA Ratings Summary
PBLA Quant Ranking